KLOW Protocol
Also known as: KLOW
Four-Peptide Regenerative Blend
Overview
KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).
Key benefits
- Theoretical synergistic multi-pathway tissue repair
- Anti-inflammatory effects across multiple mechanisms
- Cellular regeneration support
- Convenience of single injection dosing
- KPV may reduce injection site reactions versus GLOW
Mechanism of action
Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.
Molecular data
- Type
- Fixed-ratio peptide combination
Sequence
GHK-Cu + TB-500 + BPC-157 + KPV (5:1:1:1 ratio)
Blend composition
What is in the vial, and in what proportion. Each component has its own reference page.
Total 80 mg per vial.
Indications
What the research community uses this compound for, with self-reported effectiveness.
Primary Applications
Wound Healing
Most effectiveMulti-modal healing addressing tissue through complementary pathways
Post-Surgical Recovery
EffectiveEnhanced tolerability with KPV versus GLOW formulation
Sports Injury Management
EffectiveSingle injection convenience factor
Skin Rejuvenation
EffectiveCollagen stimulation and tissue regeneration
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Subcutaneous injection with rotation between abdomen, thighs, and upper arms.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Conservative approach | 200mcg total daily | Once daily evening | Subcutaneous |
| Standard research protocol | 200-500mcg total | Once daily | Subcutaneous |
| Cycling protocol | Per standard dosing | 4-6 weeks on, 2-4 weeks off | Subcutaneous |
Preparation
You will need
- KLOW 80mg vial
- Bacteriostatic water (2-5mL)
- Insulin syringes
- Alcohol prep pads
Steps
- Clean vial top with alcohol pad
- Add 4mL bacteriostatic water (creates 20mg/mL)
- Gently swirl - do not shake
- Solution should appear clear to slightly cloudy
- Label with date and concentration
- Store refrigerated immediately
- Use within 4-6 weeks
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
GLOW Protocol
AvoidKLOW contains all GLOW components plus KPV—combining causes double-dosing
Growth Hormone
AvoidMultiple components affect GH pathways; risk of excessive stimulation
Anticoagulants
MonitorComponents may affect wound healing and clotting—medical supervision required
Immunosuppressants
MonitorComponents may interfere with immunosuppressive therapy
Ipamorelin
CompatibleNo studies on combination; theoretical compatibility based on different mechanisms
NAD+
CompatibleNo data combining KLOW with NAD+; both affect cellular processes differently
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Days 1-7
Some users report inflammation reduction within days
- Week 2-4
Wound healing effects may develop if they manifest
- Week 4-6
Full cycle effects; assess response
- Break period
2-4 weeks off between cycles recommended
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions (common even with KPV)
- Individual responses vary widely
Rare side effects
- Signs of copper toxicity with prolonged use
Stop signs — stop and seek advice
- Severe injection site reactions or infection
- Allergic reactions (rash, difficulty breathing)
- Unusual fatigue or weakness
- Signs of copper toxicity (nausea, jaundice)
- Worsening of underlying conditions
Contraindications
- No safety studies on four-peptide combination
- Long-term effects completely unknown
- FDA has not approved any component for therapeutic use
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Third-party testing (Janoshik or similar)
- Reputable research supplier with quality control
- Certificate of Analysis provided
Warning signs
- Research-only status - not approved for human use
- Batch variability - ratios and purity may vary
Stop signs — don't use
- Vendors without Certificate of Analysis
- Suspiciously low prices suggest counterfeits
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
March 2025 · Alternative Therapies in Health and Medicine
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
First human IV safety study showed no adverse effects at doses up to 20 mg in 2 healthy adults, with no measurable impact on heart, liver, kidney, thyroid, or glucose biomarkers.
July 2025 · HSS Journal
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Systematic review of 36 studies (1993-2024) found BPC-157 enhances GH receptor expression and angiogenesis pathways, improving outcomes in muscle, tendon, ligament, and bone injury models.
February 2025 · Journal of Peptide Science
Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective
Review highlighting GHK-Cu's regenerative, collagen-stimulating, and anti-wrinkle properties, noting a surprising absence of clinical trials despite strong preclinical evidence.
December 2024 · Advanced Healthcare Materials
KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy
Novel KPV-rapamycin nanoparticles significantly inhibited vascular calcification in mice by suppressing inflammatory responses and activating autophagy.
References
Primary literature and clinical-trial data informing this entry.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Vasquez-Soltero JM, Margolina A · International Journal of Molecular Sciences · 2018
GHK-Cu modulates over 4,000 human genes, stimulates collagen/elastin/GAG synthesis, promotes blood vessel and nerve outgrowth, and supports tissue repair in skin, lung, bone, liver, and stomach.
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
Staresinic M, Sebecic B, Patrlj L, et al. · Journal of Orthopaedic Research · 2003
BPC-157 fully improved Achilles tendon recovery biomechanically, functionally, and microscopically; reversed HNE growth inhibition of tendocytes in vitro.
A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
Wang X, Liu L, Qi L, et al. · Journal of Cellular and Molecular Medicine · 2021
Phase I trial in 54 healthy subjects demonstrated recombinant thymosin β4 (TB-500 analog) was well tolerated and safe across ascending IV doses with no significant accumulation.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008
KPV inhibits NF-κB activation and reduces intestinal inflammation via PepT1-mediated transport; demonstrated anti-inflammatory effects in murine IBD models.
No Published Studies on KLOW Combination
N/A · 2024
No clinical or preclinical studies examine the safety or efficacy of the four-peptide KLOW combination; all evidence is extrapolated from individual component research.
Last updated . How this page was sourced is described in the methodology.